Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xuanzhu Biopharmaceutical CoFRA:V59 +3.00%11 PS Ratio is 108.83 as of Aug. 10, 2026, which is 73% below its 10-year median of 406.50. GuruFocus rates FRA:V59 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 952 Drug Manufacturers companies, Xuanzhu Biopharmaceutical Co ranks worse than 98% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Xuanzhu Biopharmaceutical Co's share price is €1.306.
Xuanzhu Biopharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.01. Hence, Xuanzhu Biopharmaceutical Co's PS Ratio for today is 108.83.
The historical rank and industry rank for Xuanzhu Biopharmaceutical Co's PS Ratio or its related term are showing as below:
FRA:V59'
s PS Ratio Range Over the Past 10 Years
Min: 89.35 Med: 406.5 Max: 1337.9
Current: 113.45
During the past 3 years, Xuanzhu Biopharmaceutical Co's highest PS Ratio was 1337.90. The lowest was 89.35. And the median was 406.50.
FRA:V59's PS Ratio is ranked worse than 98% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.35
vs FRA:V59: 113.45
Xuanzhu Biopharmaceutical Co (FRA:V59) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Xuanzhu Biopharmaceutical Co PS Ratio Related Terms
Xuanzhu Biopharmaceutical Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xuanzhu Biopharmaceutical Co PS Ratio Chart
Xuanzhu Biopharmaceutical Co Annual Data
Trend
Dec23
Dec24
Dec25
PS Ratio
0.00
0.00
572.36
Xuanzhu Biopharmaceutical Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
PS Ratio
0.00
0.00
0.00
0.00
572.36
FRA:V59 vs ZTS: PS Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Xuanzhu Biopharmaceutical Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xuanzhu Biopharmaceutical Co PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xuanzhu Biopharmaceutical Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Xuanzhu Biopharmaceutical Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Xuanzhu Biopharmaceutical Co's Share Price of today is €1.306.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Xuanzhu Biopharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Xuanzhu Biopharmaceutical Co (FRA:V59) has a PS Ratio of 108.83 as of Aug. 10, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. This is 73% below median its historical median of 406.50. Over the past decade, Xuanzhu Biopharmaceutical Co's PS Ratio has ranged from 89.35 to 1,337.90. According to the industry distribution chart, Xuanzhu Biopharmaceutical Co ranks #933 out of 952 companies in the Drug Manufacturers industry, placing it in the top 98%.
Is Xuanzhu Biopharmaceutical Co's PS Ratio too high?
Xuanzhu Biopharmaceutical Co's current PS Ratio of 108.83 is 73% below median its 10-year median of 406.50. Over the past 10 years, this metric has ranged from a low of 89.35 to a high of 1,337.90. The Drug Manufacturers industry median PS Ratio is 2.35. Xuanzhu Biopharmaceutical Co's value of 108.83 is 4531.1% above this industry median. Based on the distribution chart, Xuanzhu Biopharmaceutical Co ranks #933 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Xuanzhu Biopharmaceutical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Xuanzhu Biopharmaceutical Co's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Xuanzhu Biopharmaceutical Co ranks #933 out of 952 companies for PS Ratio. This places Xuanzhu Biopharmaceutical Co in the lower half of its industry. The industry median PS Ratio is 2.35. Xuanzhu Biopharmaceutical Co's value of 108.83 is 4531.1% above this benchmark. Historically, Xuanzhu Biopharmaceutical Co's own PS Ratio has ranged from 89.35 to 1,337.90 over the past decade. While the company's 10-year median is 406.50 vs. the industry median of 2.35, Xuanzhu Biopharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.35, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xuanzhu Biopharmaceutical Co's current PS Ratio of 108.83 is 4531.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xuanzhu Biopharmaceutical Co's current PS Ratio is 108.83, which is 73% below median its own 10-year median of 406.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xuanzhu Biopharmaceutical Co stock overvalued right now?
Xuanzhu Biopharmaceutical Co (FRA:V59) has a current PS Ratio of 108.83. The current PS Ratio is 108.83, which is 73% below median its 10-year median of 406.50 and 4531.1% above the Drug Manufacturers industry median of 2.35. Xuanzhu Biopharmaceutical Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Xuanzhu Biopharmaceutical Co (FRA:V59), the current PS Ratio is 108.83 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China's pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology, and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology, and high-growth potential therapeutic areas such as NASH.
11GF Score
Get the complete analysis for FRA:V59
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:V59 has been successfully added to your 
